Haris Charalambous

Dr. Haris Charalambous

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2014 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
Haris CharalambousHaris Charalambous
Haris Charalambous
APAthanasios Pallis
Athanasios Pallis
BHBaktiar Hasan
Baktiar Hasan
MOMary O'Brien
Mary O'Brien
To examine availability of Palliative Care (PC) services and referral patterns of European Lung cancer specialists to PC. All members of the EORTC Lung Cancer Group (LCG) were asked via email to participate in an on-line survey. 50 out of 170 (29.4%) replied: 24 medical oncologists, 14 radiation/clinical oncologists, 11 pulmonologists and 1 thoracic surgeon. All but two of respondents (96%) had access to at least one component of PC services. In terms of referral of patients to PC almost 75% of respondents would refer most of their patients when there were no treatment options or at the end of life, while only 22% would refer patients at earlier stages of disease. Barriers for referral to PC were negative attitudes of patients to PC (26%), lack of availability of PC services (20%), lack of expertise of PC physicians(18%), the belief that referral to PC signifies abandoning patients (8%), and that PC specialists discourage active oncological therapy (8%). Whilst most of the respondents expressed positive attitudes, 12-22% had overtly negative attitudes towards PC. Seventy-eight (78%) of respondents expressed an interest to participate in a trial of early PC (EPC). Despite good availability of SPC services at institutions of members of the EORTC LCG, and most respondents expressing positive attitudes towards PC, their practice involved referral of patients to PC late in the disease trajectory, hence Lung Cancer specialists in Europe have not adopted the practice of EPC concurrent with active oncological care.

19 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Galatea KallergiGalatea Kallergi
Galatea Kallergi
EKEmmanouil Kontopodis
Emmanouil Kontopodis
ANAliki Ntzifa
Aliki Ntzifa
NJNúria Jordana-Ariza
Núria Jordana-Ariza
NKNiki Karachaliou
Niki Karachaliou
AKAthanasios Kotsakis
Athanasios Kotsakis
Introduction: Liquid biopsy is a useful tool for monitoring treatment outcome in solid tumors, including lung cancer. The relevance of monitoring CTCs and plasma ctDNA as predictors of clinical outcome was assessed in EGFR-mutant NSCLC patients treated with osimertinib. Methods: Forty-seven EGFR-mutant NSCLC patients who had progressed on prior first- or second-generation EGFR inhibitors were enrolled in the study and treated with osimertinib, irrespective of the presence of the T790M mutation in the primary tumor or the plasma. Peripheral blood was collected at baseline (n = 47), post-Cycle 1 (n = 47), and at the end of treatment (EOT; n = 39). CTCs were evaluated in 32 patients at the same time points (n = 32, n = 27, and n = 21, respectively) and phenotypic characterization was performed using triple immunofluorescence staining (CK/VIM/CD45). Results: Osimertinib resulted in an ORR of 34% (2 CR) and a DCR of 76.6%. The median PFS and OS values were 7.5 (range, 0.8–52.8) and 15.1 (range, 2.1–52.8) months, respectively. ctDNA was detected in 61.7%, 27.7%, and 61.5% of patients at baseline, post-Cycle 1, and EOT, respectively. CTCs (CK+/CD45-) were detected in 68.8%, 48.1%, and 61.9% of patients at the three time points, respectively. CTCs expressing both epithelial and mesenchymal markers (CK+/VIM+/CD45-) were detected in 56.3% and 29.6% of patients at baseline and post-Cycle 1, respectively. The detection of ctDNA at baseline and post-Cycle 1 was associated with shorter PFS and OS, whereas the ctDNA clearance post-Cycle 1 resulted in a significantly longer PFS and OS. Multivariate analysis revealed that male sex and the detection of ctDNA at baseline were independent predictors of shorter PFS (HR: 2.6, 95% C.I.: 1.2–5.5, p = 0.015 and HR: 3.0, 95% C.I.: 1.3–6.9; p = 0.009, respectively). Conclusions: The decrease in both CTCs and ctDNA occurring early during osimertinib treatment is predictive of better outcome, implying that liquid biopsy monitoring may be a valuable tool for the assessment of treatment efficacy.

15 January 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
SESultan Eser
Sultan Eser
JCJenny Chang
Jenny Chang
Haris CharalambousHaris Charalambous
Haris Charalambous
BSBarbara Silverman
Barbara Silverman
ADAnna Demetriou
Anna Demetriou
HAHoda Anton-Culver
Hoda Anton-Culver
Background/Aims: There are wide variations in colorectal cancer (CRC) incidence across the world. Historically, the highest incidence rates have been reported historically in more developed countries; however, increasing trends have been seen in developing countries. Here, we present the CRC incidence pattern in Cyprus, Israel, Jordan, and İzmir, Turkey, which are countries of the Middle East Cancer Consortium (MECC). Materials and Methods: We analyzed 2005-2010 CRC data from population-based registries and calculated crude and age standardized rates for CRC, colon and rectum subsites, and annual percent changes (APCs) for trends. Results: The age-adjusted incidence rates (AAIRs) for CRC were the highest in Israeli Jews (IJ) (46.7 for males and 35.5 for females), which exceeded those of the USA Surveillance, Epidemiology, and End Result (SEER) program registries. In both sexes, AAIRs in Cyprus and Israeli Arabs (IA) were close to those in SEER registries. For both sexes, AAIRs in İzmir and Jordan were substantially lower than those in other registries. Statistically significant decreasing trends over time were observed in AAIRs for both sexes in the SEER program (APCs: males, -3.24% and females, -2.54%), whereas the trends varied within the MECC registries. There were decreasing AAIR trends for males in IJ and IA and for females in Cyprus and IJ; APC for females in IJ (-4.29%) was significant. Conversely, increasing trends with the significant APCs were observed in males in İzmir (2.43%) and Jordan (7.57%). Conclusion: MECC countries comprise both high- and low-risk populations for CRCs. However, increasing trends in low-risk populations have been alarming. Thus, the need for implementing tailored primary and secondary prevention programs in the region is essential. Cite this article as: Eser S, Chang J, Charalambous H, et al. Incidence patterns of colorectal cancers in four countries of the Middle East Cancer Consortium (Cyprus, Jordan, Israel, and İzmir, Turkey) compared with those in the United States Surveillance, Epidemiology, and End Results Program. Turk J Gastroenterol 2018; 29: 35-43.

22 December 2023 in Life
Verified
Journal Article
Open access
PDF file
CCChristos Cortas
Christos Cortas
Haris CharalambousHaris Charalambous
Haris Charalambous
Patients with differentiated thyroid cancer usually present with early-stage disease and undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent clinical outcomes and prognosis. However, a minority of patients relapse with metastatic disease, and eventually develop radioactive iodine refractory disease (RAIR). In the past there were limited and ineffective options for systemic therapy for RAIR, but over the last ten to fifteen years the emergence of tyrosine kinase inhibitors (TKIs) has provided important new avenues of treatment for these patients, that are the focus of this review. Currently, Lenvatinib and Sorafenib, multitargeted TKIs, represent the standard first-line systemic treatment options for RAIR thyroid carcinoma, while Cabozantinib is the standard second-line treatment option. Furthermore, targeted therapies for patients with specific targetable molecular abnormalities include Latrectinib or Entrectinib for patients with NTRK gene fusions and Selpercatinib or Pralsetinib for patients with RET gene fusions. Dabrafenib plus Trametinib currently only have tumor agnostic approval in the USA for patients with BRAF V600E mutations, including thyroid cancer. Redifferentiation therapy is an area of active research, with promising initial results, while immunotherapy studies with checkpoint inhibitors in combination with tyrosine kinase inhibitors are underway.

1 April 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
Haris CharalambousHaris Charalambous
Haris Charalambous
EPE. Protopapa
E. Protopapa
DGD. Gavrielidou
D. Gavrielidou
VAV. Avgousti
V. Avgousti
Prescription of opioids based on morphine equivalence data per capita is very low in Cyprus. Three studies were undertaken to evaluate the prescribing habits of physicians in Cyprus for cancer patients with pain. Data were collected regarding the presence and severity of pain and prescription of analgesia in a cross-sectional study of 141 patients receiving outpatient chemotherapy within the Bank of Cyprus Oncology Centre (BOCOC), in a retrospective study of 90 new lung cancer patients referred to one Oncologist in the BOCOC, and in a prospective study of 100 new cancer patients referred to the BOCOC. In the first study, the results reflected the prescribing habits of oncologists within the oncology centre, whilst the second and third studies reflected the prescribing habits of physicians outside the oncology centre. In the three studies, 56.0%, 48.1% and 57.7%, respectively, of patients with pain were prescribed analgesia. The majority of patients were prescribed paracetamol and non-steroidal anti-inflammatory drugs, and only 8.6%, 11.5% and 0%, respectively, of patients were prescribed strong opioids. In the last two studies, following their oncology appointment the prescription of analgesia to patients with pain, increased to 80.8% and 73.1%, respectively, whilst the prescription of strong opioids, increased to 28.8% and 34.6%, respectively, reflecting oncologists' practice. There is under-treatment of pain in cancer patients, both within and outside a tertiary oncology centre in Cyprus. Particularly there is low prescribing of strong opioids. There is a need to look further into the barriers that prevent physicians prescribing opioids in Cyprus, as well as to patients' attitudes towards analgesia and opioids, and to set up training programs to address these issues.

12 May 2025 in Thoracic Cancer
Verified
Journal Article
Open access
Haris CharalambousHaris Charalambous
Haris Charalambous
CBCameron Brown
Cameron Brown
PVParis Vogazianos
Paris Vogazianos
KKKyriaki Katsaounou
Kyriaki Katsaounou
ENElpiniki Nikolaou
Elpiniki Nikolaou
AAAthos Antoniades
Athos Antoniades
Background: The gut microbiome influences the host immune system, cancer development and progression, as well as the response to immunotherapy during cancer treatment. Here, we analyse the composition of the gut bacteriome in metastatic Non‐Small Cell Lung Cancer (NSCLC) patients receiving Pembrolizumab immunotherapy within a prospective maintenance trial through opportunistic sampling during treatment.Methods: The gut microbiome profiles of NSCLC patients were obtained from stool samples collected during Pembrolizumab treatment and analysed with 16S rRNA metagenomics sequencing. Patient profiles were compared to a group of healthy individuals of matching ethnic group, age, sex, BMI and comorbidities.Results: A significant decrease in the treated patients was observed in two prominent bacterial families of the phylum Firmicutes, Lachnospiraceae and Ruminoccocaceae, which comprised 31.6% and 21.8% of the bacteriome in the healthy group but only 10.9% and 14.2% in the treated patient group, respectively. Species within the Lachnospiraceae and Ruminococcaceae families are known to break down undigested carbohydrates generating short chain fatty acids (SCFA), such as butyrate, acetate and propionate as their major fermentation end‐products, which have been implicated in modifying host immune responses. In addition, a significant increase of the Bacteroidacaeae family (Bacteroidetes phylum) was observed from 10.7% in the healthy group to 23.3% in the treated patient group. Moreover, and in agreement with previous studies, a decrease in the Firmicutes to Bacteroidetes ratio in the metastatic NSCLC Pembrolizumab‐treated patients was observed.Conclusion: The observed differences indicate dysbiosis and a compromised intestinal health status in the metastatic NSCLC Pembrolizumab‐treated patients. This data could inform future studies of immunotherapy treatment responses and modulation of the gut microbiome to minimise dysbiosis prior or concurrent to treatment.Trial Registration: SWIPE Trial (NCT 02705820).